Dr Reddy's Generic Ozempic Gets Brazil Approval

Indian pharmaceutical company Dr Reddy’s Laboratories has secured regulatory approval in Brazil to market its generic semaglutide injection, opening another international market for its diabetes treatment portfolio.

Brazil’s National Health Surveillance Agency (ANVISA) has authorised the company’s semaglutide product for adults with insufficiently controlled type 2 diabetes, to be used alongside diet and exercise. The approval covers once-weekly administration through pre-filled injector pens in 2 mg and 4 mg presentations, according to Reuters.

The development provides a further step in Dr Reddy’s international expansion strategy for generic semaglutide, the active pharmaceutical ingredient used in Novo Nordisk’s diabetes treatment Ozempic and weight-management medicine Wegovy.

Brazil represents a significant potential market for the drugmaker. The company said the country has approximately 16.6 million adults aged between 20 and 79 living with diabetes, making it the sixth-largest country globally by adult diabetes population.

ANVISA approval strengthens Dr Reddy’s Brazil expansion

The Brazilian regulatory approval follows an earlier setback in April, when ANVISA rejected Dr Reddy’s application because it did not satisfy all regulatory requirements.

The company has subsequently secured the authorisation, allowing it to move forward with plans to commercialise its generic semaglutide product in Brazil.

ANVISA’s published regulatory information dated October 29, 2026, lists Embeltah, a semaglutide medicine registered to Dr. Reddy’s Farmacêutica do Brasil Ltda, with manufacturing by India’s OneSource Specialty. The regulator identifies the product as a treatment for diabetes.

This regulatory development is part of a wider expansion of semaglutide-based medicines in Brazil, where authorities have been processing applications for additional GLP-1 treatments.

Generic semaglutide remains a growth priority

Dr Reddy’s has identified generic semaglutide as an important growth opportunity across India and selected international markets.

Semaglutide belongs to the glucagon-like peptide-1 (GLP-1) class of medicines, which is used in the treatment of type 2 diabetes. The active ingredient is also used in other formulations approved for weight management.

However, the Brazilian approval reported in this development specifically covers treatment of insufficiently controlled type 2 diabetes. It should not be interpreted as authorisation for weight-loss treatment.

The company plans to make the product available as a pre-filled injector pen in two strengths, supporting once-weekly administration.

The Brazilian market is strategically relevant because of its large diabetes population and the growing availability of semaglutide-based medicines. For generic drug manufacturers, regulatory approvals in major international markets can create opportunities to expand distribution and build commercial partnerships.

Canada recall adds a quality-control challenge

Dr Reddy’s international semaglutide expansion has also faced a product-quality challenge in Canada.

The company recalled batches of its generic semaglutide earlier in 2026 after identifying an impurity in the active pharmaceutical ingredient.

According to Reuters, Dr Reddy’s plans to relaunch the medicine in Canada during the fourth quarter of 2026. The company is also targeting additional launches across Latin America and Africa in the coming months.

The Canadian recall highlights the importance of manufacturing quality, regulatory compliance and supply-chain oversight as pharmaceutical companies expand complex injectable medicines into international markets.

For Dr Reddy’s, successful execution across these markets will depend not only on securing regulatory approvals but also on maintaining consistent product quality and establishing reliable distribution arrangements.

Brazil approval supports Dr Reddy’s international growth strategy

The latest approval strengthens Dr Reddy’s position in the international generic semaglutide market, where pharmaceutical companies are seeking opportunities following the expansion of GLP-1-based treatments.

Brazil’s sizeable diabetes population provides a potential commercial opportunity, while the company’s broader plans across Latin America and Africa could support further geographic expansion.

The next developments to watch include the commercial launch of the Brazilian product, progress with the planned Canadian relaunch and additional regulatory approvals across international markets.

For the Indian pharmaceutical industry, Dr Reddy’s progress illustrates the importance of developing complex generic medicines and securing regulatory access in major overseas markets.

Follow B2B Market Signal on social media for the latest business news, industry developments, market intelligence and analysis. Connect with us on LinkedIn and follow us on Instagram at @b2bmarketsignal for regular updates